Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections[1][2][3].
Molecular Formula
C485H618F9N158Na40O294P39S6
Smiles
[Elebsiransodium]
Target
HBV; Small Interfering RNA (siRNA)
Purity
95.83
Solubility
H2O : ≥ 100 mg/mL
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
